Crawford faces obstacles in nomination process

Lester Crawford's nomination to head the FDA won committee approval on Wednesday but is still facing some major hurdles before reaching a full Senate vote.
Although the Senate committee on Health, Education, Labor and Pensions approved the nomination, Sens. Patty Murray, D-Wash., and Hillary Clinton, D-N.Y., have placed a hold on Crawford's nomination, blocking immediate consideration of it.
The hold will remain in place until the FDA issues a yes or no decision on allowing OTC sales of Barr Pharmaceuticals' emergency contraceptive Plan B. In January, an FDA advisory panel recommended 24-3 in favor of OTC status for the drug but at press time the agency had yet to make a final determination on the matter.
You must be a registered member of MMM to post a comment.

A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.

Email Newsletters


Pharma continues to struggle with its image. Exhibit A is the public debate around the price of, and access to, new and innovative meds. As countless transformative technologies hit market, has industry done enough to anchor its permission to innovate? To provide a closer look at trends affecting trust over the past year, MM&M presents this e-book, "The 2015 Edelman Trust Barometer." Click here.